Information for the public

Venetoclax (Venclyxto) is available on the NHS as a possible treatment for chronic lymphocytic leukaemia in adults if:

  • they have a 17p deletion or TP53 mutation and a B‑cell receptor pathway inhibitor is unsuitable, or if their disease has gotten worse after a B‑cell receptor pathway inhibitor or
  • they don’t have a 17p deletion or TP53 mutation, and their disease has gotten worse after both chemo-immunotherapy and a B‑cell receptor pathway inhibitor.

Information and support

NHS Choices may be a good place to find out more.

These organisations can give you advice and support:

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-2665-7


This page was last updated: 08 November 2017